339 related articles for article (PubMed ID: 9784556)
21. Immunogenicity and reactogenicity of a booster dose of a novel combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine given to toddlers of 13-14 months of age with antibody persistence up to 31 months of age.
Tejedor JC; Moro M; Merino JM; Gómez-Campderá JA; García-del-Rio M; Jurado A; Díez-Delgado FJ; Omeñaca F; García-Sicilia J; Ruiz-Contreras J; Martin-Ancel A; Roca J; Boceta R; García-Corbeira P; Maechler G; Boutriau D;
Pediatr Infect Dis J; 2008 Jul; 27(7):579-88. PubMed ID: 18536619
[TBL] [Abstract][Full Text] [Related]
22. Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. II. Specificity.
Rubinstein LJ; Stein KE
J Immunol; 1988 Dec; 141(12):4357-62. PubMed ID: 3143763
[TBL] [Abstract][Full Text] [Related]
23. Meningococcal serogroup C immunogenicity, antibody persistence and memory B-cells induced by the monovalent meningococcal serogroup C versus quadrivalent meningococcal serogroup ACWY conjugate booster vaccine: A randomized controlled trial.
van Ravenhorst MB; van der Klis FRM; van Rooijen DM; Knol MJ; Stoof SP; Sanders EAM; Berbers GAM
Vaccine; 2017 Aug; 35(36):4745-4752. PubMed ID: 28668575
[TBL] [Abstract][Full Text] [Related]
24. Dose dependency of antibody response in infants and children to pneumococcal polysaccharides conjugated to tetanus toxoid.
Ahman H; Käyhty H; Vuorela A; Leroy O; Eskola J
Vaccine; 1999 Jun; 17(20-21):2726-32. PubMed ID: 10418924
[TBL] [Abstract][Full Text] [Related]
25. Conjugation of β-glucan markedly increase the immunogencity of meningococcal group Y polysaccharide conjugate vaccine.
Qiao W; Ji S; Zhao Y; Hu T
Vaccine; 2015 Apr; 33(17):2066-72. PubMed ID: 25728319
[TBL] [Abstract][Full Text] [Related]
26. Two different methods result in the selection of peptides that induce a protective antibody response to Neisseria meningitidis serogroup C.
Prinz DM; Smithson SL; Westerink MA
J Immunol Methods; 2004 Feb; 285(1):1-14. PubMed ID: 14871530
[TBL] [Abstract][Full Text] [Related]
27. Safety, tolerability, and immunogenicity of concurrent administration of Haemophilus influenzae type b conjugate vaccine (meningococcal protein conjugate) with either measles-mumps-rubella vaccine or diphtheria-tetanus-pertussis and oral poliovirus vaccines in 14- to 23-month-old infants.
Dashefsky B; Wald E; Guerra N; Byers C
Pediatrics; 1990 Apr; 85(4 Pt 2):682-9. PubMed ID: 2107519
[TBL] [Abstract][Full Text] [Related]
28. Murine immune response to the Neisseria meningitidis group C capsular polysaccharide. I. Ontogeny.
Rubinstein LJ; Stein KE
J Immunol; 1988 Dec; 141(12):4352-6. PubMed ID: 3143762
[TBL] [Abstract][Full Text] [Related]
29. Safety and immunogenicity of a Haemophilus influenzae type B polysaccharide-tetanus toxoid conjugate vaccine combined with diphtheria, tetanus and pertussis vaccines in Thai infants.
Chotpitayasunondh T; Panpitpat C; Thisyakorn U; Furer E; Que JU; Hasler T; Cryz SJ
Southeast Asian J Trop Med Public Health; 1997 Mar; 28(1):91-8. PubMed ID: 9322290
[TBL] [Abstract][Full Text] [Related]
30. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides. II. Increased susceptibility to fatal pneumococcal sepsis due to absence of anti-polysaccharide IgG3 is corrected by induction of anti-polysaccharide IgG1.
McLay J; Leonard E; Petersen S; Shapiro D; Greenspan NS; Schreiber JR
J Immunol; 2002 Apr; 168(7):3437-43. PubMed ID: 11907102
[TBL] [Abstract][Full Text] [Related]
31. High antibody responses to booster doses of either Haemophilus influenzae capsular polysaccharide or conjugate vaccine after primary immunization with conjugate vaccines.
Käyhty H; Eskola J; Peltola H; Saarinen L; Mäkelä PH
J Infect Dis; 1992 Jun; 165 Suppl 1():S165-6. PubMed ID: 1588156
[No Abstract] [Full Text] [Related]
32. Co-administration of a novel Haemophilus influenzae type b and Neisseria meningitidis serogroups C and Y-tetanus toxoid conjugate vaccine does not interfere with the immune response to antigens contained in infant vaccines routinely used in the United States.
Marshall GS; Marchant CD; Blatter M; Friedland LR; Aris E; Miller JM
Hum Vaccin; 2011 Feb; 7(2):258-64. PubMed ID: 21307655
[TBL] [Abstract][Full Text] [Related]
33. Effect of immunity to the carrier protein on antibody responses to Haemophilus influenzae type b conjugate vaccines.
Granoff DM; Rathore MH; Holmes SJ; Granoff PD; Lucas AH
Vaccine; 1993; 11 Suppl 1():S46-51. PubMed ID: 8447176
[TBL] [Abstract][Full Text] [Related]
34. Comparison of Neisseria meningitidis serogroup W135 polysaccharide-tetanus toxoid conjugate vaccines made by periodate activation of O-acetylated, non-O-acetylated and chemically de-O-acetylated polysaccharide.
Gudlavalleti SK; Lee CH; Norris SE; Paul-Satyaseela M; Vann WF; Frasch CE
Vaccine; 2007 Nov; 25(46):7972-80. PubMed ID: 17936445
[TBL] [Abstract][Full Text] [Related]
35. Gamma 3 gene-disrupted mice selectively deficient in the dominant IgG subclass made to bacterial polysaccharides undergo normal isotype switching after immunization with polysaccharide-protein conjugate vaccines.
Shapiro DA; Threadgill DS; Copfer MJ; Corey DA; McCool TL; McCormick LL; Magnuson TR; Greenspan NS; Schreiber JR
J Immunol; 1998 Oct; 161(7):3393-9. PubMed ID: 9759856
[TBL] [Abstract][Full Text] [Related]
36. Five-year antibody persistence and safety following a booster dose of combined Haemophilus influenzae type b-Neisseria meningitidis serogroup C-tetanus toxoid conjugate vaccine.
Tejedor JC; Merino JM; Moro M; Navarro ML; Espín J; Omeñaca F; García-Sicilia J; Moreno-Pérez D; Ruiz-Contreras J; Centeno F; Barrio F; Cabanillas L; Muro M; Esporrin C; De Torres MJ; Caubet M; Boutriau D; Miller JM; Mesaros N
Pediatr Infect Dis J; 2012 Oct; 31(10):1074-7. PubMed ID: 22828645
[TBL] [Abstract][Full Text] [Related]
37. Immunologic priming by one dose of Haemophilus influenzae type b conjugate vaccine in infancy.
Kurikka S; Käyhty H; Saarinen L; Rönnberg PR; Eskola J; Mäkelä PH
J Infect Dis; 1995 Nov; 172(5):1268-72. PubMed ID: 7594663
[TBL] [Abstract][Full Text] [Related]
38. Elevated levels of maternal anti-tetanus toxin antibodies do not suppress the immune response to a Haemophilus influenzae type b polyribosylphosphate-tetanus toxoid conjugate vaccine.
Panpitpat C; Thisyakorn U; Chotpitayasunondh T; Fürer E; Que JU; Hasler T; Cryz SJ
Bull World Health Organ; 2000; 78(3):364-71. PubMed ID: 10812736
[TBL] [Abstract][Full Text] [Related]
39. Neisseria meningitidis serogroup C polysaccharide and serogroup B outer membrane vesicle conjugate as a bivalent meningococcus vaccine candidate.
Fukasawa LO; Gorla MC; Schenkman RP; Garcia LR; Carneiro SM; Raw I; Tanizaki MM
Vaccine; 1999 Aug; 17(23-24):2951-8. PubMed ID: 10462229
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity of a Haemophilus influenzae polysaccharide-Neisseria meningitidis outer membrane protein complex conjugate vaccine.
Donnelly JJ; Deck RR; Liu MA
J Immunol; 1990 Nov; 145(9):3071-9. PubMed ID: 2120344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
